UW study plays pivotal role in today’s FDA approval of HIV prevention drug

The U.S. Food and Drug Administration decided today, July 16,  to approve the use of an HIV treatment drug for reducing the risk of acquiring HIV.

Following the recommendation of the Antiviral Drugs Advisory Committee made on May 10, the FDA approved the medication generically known as combination emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, branded as Truvada®), for HIV prophylaxis for people who test HIV negative.  Truvada® is manufactured by Gilead Sciences Inc. in Foster City, Calif., and is currently prescribed with other HIV drugs for treatment of those infected with the virus.

In evaluating whether to allow Truvada® to be prescribed for HIV prevention purposes for those who are not HIV infected, the FDA reviewed the evidence from two studies – the largest of which was conducted by the University of Washington’s International Clinical Research Center (ICRC).

Read more at the UW Today website.